Shots:

• The two P-III trials i.e. COAST-V (N=341) & COAST-W (N=316) involves assessing of Taltz (80/160 mg- q4w/q2w) SC vs adalimumab- or PBO in patients with AS never undergone bDMARD drug and intolerant to TNF inhibitors respectively
• COAST-V and COAST-W Results: @16 wks.: ASAS40 (48%- 25%; 52% -31% vs 18%- 13%); ASAS20 (64%- 48%; 69%- 47% vs 40%- 25%); BASDAI50 (42%- 43% vs 17%): (-2.2 ± 0.2- -2.1 ± 0.2 & -0.9 ± 0.2); MRI Spine SPARCC CFB: (-11.0- -11.0; -9.6- -9.6 vs -1.5- -1.5)
• Taltz is a mAb binds with interleukin 17A (IL-17A)- and is approved treatment for PA & moderate-to-severe plaque psoriasis in adults. Lilly plans to file BLA under the US FDA with reference to above results in AS/radiographic axSpA

/ article | Ref: Eli Lilly | Image: Bolon